BRAF V600E Mutation in Odontogenic Keratocyst: A Systematic Review and Meta-Analysis

Jéssica da Silva Cunha; Lucas Nascimento Ribeiro; Allan Vinícius Martins-de-Barros; Raisa Jordana Geraldine Severino-Lazo; Raíssa Soares dos Anjos; Renata de Albuquerque Cavalcanti Almeida; Mohammed N. Islam; Marianne de Vasconcelos Carvalho

Authors

Jéssica da Silva Cunha
Lucas Nascimento Ribeiro
Allan Vinícius Martins-de-Barros
Raisa Jordana Geraldine Severino-Lazo
Raíssa Soares dos Anjos
Renata de Albuquerque Cavalcanti Almeida
Mohammed N. Islam
Marianne de Vasconcelos Carvalho

Keywords:

Odontogenic Cysts, Proto-Oncogene Proteins B-raf, Polymerase Chain Reaction

Abstract

Objective: To assess the frequency of the BRAF V600E mutation in odontogenic keratocyst, correlating the methods of evaluation and detection of the mutated protein. Material and Methods: This systematic review was conducted following the PRISMA guidelines and registered in PROSPERO (CRD 42022379570). An electronic search was performed up to January 20th, 2024, in the databases of Medline, Scopus, Embase, and gray literature (Google Scholar, BDTD). One hundred and sixty-six cases in seven studies were included. The methodological quality of the studies was performed according to the Joanna Briggs Institute. Results: Only two of the seven studies reported positivity for the BRAF V600E mutation, both by molecular methods. In the remaining five studies, the BRAF V600E mutation was not present, one evaluated by RT-PCR, three by DNA sequencing, and one by IHC. Conclusion: Through analysis of the articles, the BRAF V600E gene mutation alone does not play a significant role in the pathogenesis of OKC. Further research and new studies are necessary.

References

Soluk-Tekkesin M, Wright JM. The World Health Organization classification of odontogenic lesions: A summary of the changes of the 2022 (5th) edition. Turk Patoloji Derg 2022; 38(2):168-184. https://doi.org/10.5146/tjpath.2022.01573

Mohanty S, Dabas J, Verma A, Gupta S, Urs AB, Hemavathy S. Surgical management of the odontogenic keratocyst: A 20-year experience. Int J Oral Maxillofac Surg 2021; 50(9):1168-1176. https://doi.org/10.1016/j.ijom.2021.02.015

Cha YH, Cho ES, Kang HE, Ko J, Nam W, Kim HJ, et al. Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst. Oral Oncol 2017; 74:62-67. https://doi.org/10.1016/j.oraloncology.2017.09.016

Cantwell-Dorris ER, O’Leary JJ, Sheils OM. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011; 10(3):385-394. https://doi.org/10.1158/1535-7163.MCT-10-0799

Loo E, Khalili P, Beuhler K, Siddiqi I, Vasef MA. BRAF V600E mutation across multiple tumor types: Correlation between dna-based sequencing and mutation-specific immunohistochemistry. Appl Immunohistochem Mol Morphol 2018; 26(10):709-713. https://doi.org/10.1097/PAI.0000000000000516

You Z, Liu SP, Du J, Wu YH, Zhang SZ. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review. J Oral Pathol Med 2019; 48(3):201-205. https://doi.org/10.1111/jop.12807

Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet 2014; 46(7):722-725. https://doi.org/10.1038/ng.2986

Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res 2014; 20(21):5517-5526. https://doi.org/10.1158/1078-0432.CCR-14-1069

Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 2014; 232(5):492-498. https://doi.org/10.1002/path.4317

Brunner P, Bihl M, Jundt G, Baumhoer D, Hoeller S. BRAF p.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology. Oral Oncol 2015; 51(10):e77-78. https://doi.org/10.1016/j.oraloncology.2015.07.010

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372:n71. https://doi.org/10.1136/bmj.n71

Moola S, Munn Z, Sears K, Sfetcu R, Currie M, Lisy K, et al. Conducting systematic reviews of association (etiology): The Joanna Briggs Institute’s approach. Int J Evid Based Healthc 2015; 13(3):163-169. https://doi.org/10.1097/XEB.0000000000000064

França JA, de Sousa SF, Diniz MG, Pereira TDSF, de Resende TAC, Santos JND, et al. Absence of BRAFV600E mutation in odontogenic keratocysts. J Oral Pathol Med 2018; 47(2):186-191. https://doi.org/10.1111/jop.12671

Jain KS, Bodhankar K, Desai RS, Bansal S, Shirsat P, Prasad P, et al. Absence of BRAFV600E immunohistochemical expression in sporadic odontogenic keratocyst, syndromic odontogenic keratocyst and orthokeratinized odontogenic cyst. J Oral Pathol Med 2020; 49(10):1061-1067. https://doi.org/10.1111/jop.13081

Zhang R, Yang Q, Qu J, Hong Y, Liu P, Li T. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts. Oral Surg Oral Med Oral Pathol Oral Radiol 2020; 129(3):229-235. https://doi.org/10.1016/j.oooo.2019.04.001

Zhang R, Yang J, Zhang J, Hong Y, Xie X, Li T. Should the solid variant of odontogenic keratocyst and keratoameloblastoma be classified as the same entity? A clinicopathological analysis of nine cases and a review of the literature. Pathology 2021; 53(4):478-486. https://doi.org/10.1016/j.pathol.2020.09.028

Shimura M, Nakashiro KI, Sawatani Y, Hasegawa T, Kamimura R, Izumi S, et al. Whole exome sequencing of SMO, BRAF, PTCH1 and GNAS in odontogenic diseases. In Vivo 2020; 34(6):3233-3240. https://doi.org/10.21873/invivo.12159

Kahraman D, Gunhan O, Celasun B. A series of 240 odontogenic keratocysts: Should we continue to use the terminology of ‘keratocystic odontogenic tumour’ for the solid variant of odontogenic keratocyst J Craniomaxillofac Surg 2018; 46(6):942. https://doi.org/10.1016/j.jcms.2018.04.007

Santana DCP, Xavier FCA, Santos JND, Henriques ÁCG. Is the solid variant of odontogenic keratocyst the neoplastic counterpart of the lesion? Oral Dis 2022; 28(8):2215-2218. https://doi.org/10.1111/odi.14157

Guo YY, Zhang JY, Li XF, Luo HY, Chen F, Li TJ. PTCH1 gene mutations in keratocystic odontogenic tumors: A study of 43 Chinese patients and a systematic review. PLoS One 2013; 8(10):e77305. https://doi.org/10.1371/journal.pone.0077305

Khan AA, Qahtani S Al, Dawasaz AA, Saquib SA, Asif SM, Ishfaq M, et al. Management of an extensive odontogenic keratocyst: A rare case report with 10-year follow-up. Medicine 2019; 98(51):e17987. https://doi.org/10.1097/MD.0000000000017987

Valdivia ADCM, Ramos-Ibarra ML, Franco-Barrera MJ, Arias-Ruiz LF, García-Cruz JM, Torres-Bugarín O. What is currently known about odontogenic keratocysts? Oral Health Prev Dent 2022; 20(1):321-330. https://doi.org/10.3290/j.ohpd.b3240829

Martins-de-Barros AV, Anjos RSD, Silva CCG, Silva EDOE, Araújo FADC, Carvalho MV. Diagnostic accuracy of immunohistochemistry compared with molecular tests for detection of BRAF V600E mutation in ameloblastomas: Systematic review and meta-analysis. J Oral Pathol Med 2022; 51(3):223-230. https://doi.org/10.1111/jop.13278

Fisher KE, Cohen C, Siddiqui MT, Palma JF, Lipford EH, Longshore JW. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. Hum Pathol 2014; 45(11):2281-2293. https://doi.org/10.1016/j.humpath.2014.07.014